Page last updated: 2024-12-11
khafrefungin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
khafrefungin: inhibits inositol phosphoceramide synthase in fungi; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9851575 |
| CHEMBL ID | 1631582 |
| MeSH ID | M0284714 |
Synonyms (5)
| Synonym |
|---|
| bdbm50333121 |
| khafrefungin |
| CHEMBL1631582 , |
| (2s,3s,4r)-2,3,5-trihydroxy-4-[(2e,4r,6e,8e,10s,11r,12s)-11-hydroxy-2,4,6,8,10,12-hexamethyl-5-oxodocosa-2,6,8-trienoyl]oxypentanoic acid |
| Q58049114 |
Research Excerpts
Overview
Khafrefungin is an antifungal agent. It inhibits inositol phosphorylceramide (IPC) synthase, an enzyme involved in fungal sphingolipid biosynthesis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Khafrefungin is an antifungal agent that inhibits inositol phosphorylceramide (IPC) synthase, an enzyme involved in fungal sphingolipid biosynthesis." | ( Chemistry and biology of khafrefungin. Large-scale synthesis, design, and structure-activity relationship of khafrefungin, an antifungal agent. Hanada, K; Kobayashi, S; Mori, Y; Nakamura, M; Okuyama, K; Tanikawa, K; Yasuda, S, 2003) | 1.34 |
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Khafrefungin does not inhibit the synthesis of mammalian sphingolipids thus making this the first reported compound that is specific for the fungal pathway." | ( Khafrefungin, a novel inhibitor of sphingolipid synthesis. Bull, HG; Garcia-Calvo, M; Kurtz, MB; Mandala, SM; Milligan, J; Rosenbach, M; Thornton, RA, 1997) | 2.46 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Inositol phosphorylceramide synthase | Candida albicans SC5314 | IC50 (µMol) | 0.0006 | 0.0002 | 0.0004 | 0.0006 | AID542410 |
| Inositol phosphorylceramide synthase | Candida albicans SC5314 | Ki | 0.0004 | 0.0002 | 0.0004 | 0.0005 | AID542405 |
| Inositol phosphorylceramide synthase catalytic subunit AUR1 | Saccharomyces cerevisiae S288C | IC50 (µMol) | 5.6715 | 0.0002 | 0.0216 | 0.0430 | AID542406; AID542407 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID542410 | Inhibition of Candida albicans inositol phosphorylceramide synthase | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. |
| AID542404 | Inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. |
| AID542406 | Inhibition of Saccharomyces cerevisiae SJ21R inositol phosphorylceramide synthase preincubated for 30 mins | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. |
| AID542405 | Inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase preincubated for 30 mins | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. |
| AID542407 | Inhibition of aureobasidin A-resistant Saccharomyces cerevisiae inositol phosphorylceramide synthase preincubated for 30 mins | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.21
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.21) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (18.18%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (81.82%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||